Abstract:BACKGROUND:Despite recent advances in the treatment of hepatocellular carcinoma (HCC), the chemotherapy efficacy against HCC is still unsatisfactory. The mammalian target of rapamycin (mTOR) has been emerged as an important cancer therapeutic target. However, HCC cells often resistant to rapamycin because of the paradoxical activation of Akt by rapamycin. In this study, we investigated whether bortezomib could enhance the antitumor effects of rapamycin.METHODS:The effects of rapamycin and bortezomib on HCC proliferation, apoptosis, migration, and invasiveness in vitro were assessed by CCK-8 analysis, flow cytometry, Hoechst 33342 staining and transwell assays, respectively. Total and phosphorylated protein levels of Akt were detected by Western blotting. The effects of rapamycin and/or bortezomib on the mRNA expression levels of p53, p27, p21 and Bcl-2 family in HCCLM3 cells were evaluated by RT-PCR. The roles of rapamycin and bortezomib on HCC growth and metastasis in xenograft models were evaluated by tumor volumes and fluorescent signals. The effects of rapamycin and bortezomib on cell proliferation and apoptosis in vivo were test by PCNA and TUNEL staining.RESULTS:Bortezomib synergized with rapamycin to reduce cell growth, induce apoptosis, and inhibit cell mobility in vitro. Further mechanistic studies showed that bortezomib inhibited rapamycin-induced phosphorylated Akt, which in turn enhanced apoptosis of HCC cell lines. The alteration of the mRNA expression of cell cycle inhibitors p53, p27, p21 and apoptosis associated genes Bcl-2, Bax were also involved in the synergistic antitumor effects of rapamycin and bortezomib. P53 inhibitor PFT-α significantly attenuate the effect of rapamycin and bortezomib on cell apoptosis, which indicated that the pro-apoptotic effect of rapamycin and bortezomib may be p53-dependent. Treatment of HCCLM3-R bearing nude mice with rapamycin and bortezomib significantly enhanced tumor growth inhibition (72.4%), comparing with either rapamycin- (54.7%) or bortezomib-treated mice (22.4%). In addition, the lung metastasis was significantly suppressed in mice received the combination treatment (16.6%). The combination treatment of rapamycin and bortezomib significantly inhibited tumor cell proliferation and tumor angiogenesis in vivo.CONCLUSION:The combination of rapamycin with bortezomib could be a novel and promising therapeutic approach to the treatment of HCC.

[Effect of Chemotherapy with Cisplatin and Rapamycin Against Hep-2 Cells in Vitro].

Combined Effect of Rapamycin and Cisplatin on Survival of Hep-2 Cells in Vitro

Combination of Cetuximab and Rapamycin Enhances the Therapeutic Efficacy in Hepatocellular Carcinoma.

Mutual Effect of Cisplatin and Radiation Used in Combination in Hep-2 Cells

The effect of rapamycin combined with cisplatin on apoptosis and cell cycle distribution of human ovarian cancer SKOV3 cells

(−)-Epigallocatechin-3-gallate derivatives combined with cisplatin exhibit synergistic inhibitory effects on non-small-cell lung cancer cells

The Studies of Antitumor Effect of Rapamycin on Human Hepatocellular Carcinoma BEL-7402 Cells in vitro

Novel Synergistic Antitumor Effects of Rapamycin with Bortezomib on Hepatocellular Carcinoma Cells and Orthotopic Tumor Model

Effect of emodin combined with cisplatin on the invasion and migration of HepG2 hepatoma cells

Rapamycin enhances chemosensitivity of endometrial cancer cells to adria mycin

Study of mechanism in growth inhibition of human lung Study of mechanism in growth inhibition of human lung adenocarcinoma with combined use of NS-398 and cisplatin

Intervention Effects of Nedaplatin and Cisplatin on Proliferation and Apoptosis of Human Tumour Cells in Vitro

Berberine Sensitizes Rapamycin-Mediated Human Hepatoma Cell Death in Vitro

Rapamycin Enhances Cetuximab Cytotoxicity by Inhibiting Mtor-Mediated Drug Resistance in Mesenchymal Hepatoma Cells

Effect of Rapamycin Alone and in Combination with Sorafenib in an Orthotopic Model of Human Hepatocellular Carcinoma.

Resveratrol enhances the antiliver cancer effect of cisplatin by targeting the cell membrane protein PLA2

Synergistic effect of mTOR inhibitor rapamycin and fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells.

Rapamycin Enhances Apoptosis and Increases Sensitivity to Cisplatin In-Vitro

Rapamycin enhances the anti-tumor effect of gemcitabine in pancreatic cancer cells

Antiproliferative and Overadditive Effects of Rapamycin and FTY720 in Pancreatic Cancer Cells in Vitro

Effects of curcumin combined with cisplatin on cell proliferation, apoptosis, migration and invasion in hepatocarcinoma HepG2 cell